Investigational HBV core inhibitor shows early clinical promise

BARCELONA – An investigational drug that targets the hepatitis B virus (HBV) core protein is a “totally new approach” to treating chronic HBV infection according to the results of an early-phase...
Source: Family Practice News - Category: Primary Care Source Type: news